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Background: Capecitabine (Xelodaw) is a novel, oral, selectively tumor-activated fluoropyrimidine
with proven activity in the treatment of advanced colorectal cancer. This trial was conducted to
evaluate the efficacy, safety and feasibility of capecitabine in previously untreated patients with
advanced and/or metastatic gastric cancer, with a view to replacing 5-fluorouracil (5-FU) in such
patients.
Patients and methods: Forty-four patients received capecitabine 1250 mg/m2 twice daily
(2500 mg/m2/day) for 14 days followed by 7 days of rest, for up to six cycles.
Results: Capecitabine produced an objective response rate of 34% (all partial responses) and stable
disease in 14 patients (30%). The median time to disease progression (TTP) was 3.2 months [95%
confidence interval (CI) 2.7–6.4 months] and median overall survival was 9.5 months (95% CI
6.9–13.2 months). Hand-foot syndrome (HFS), nausea, anorexia, diarrhea and vomiting were the
most common adverse events. While HFS was the most frequent grade 3/4 toxicity (National Cancer
Institute Common Toxicity Criteria), only 9% of patients experienced grade 3 HFS. Severe myelo-
suppression was not reported during the study.
Conclusions: Capecitabine monotherapy is active and well tolerated as first-line therapy in patients
with advanced/metastatic gastric cancer. Larger comparative trials investigating capecitabine-based
combination regimens in patients with advanced gastric cancer are warranted.
Key words: capecitabine, gastric cancer, metastatic, untreated
Introduction
Gastric cancer is the most frequently diagnosed cancer and one
of the leading causes of cancer-related death in Korea [1].
While 5-fluorouracil (5-FU) is the most effective single agent,
objective responses tend to be <20%, and of partial and short
duration. Continuous infusions of 5-FU are more active than
intravenous bolus administration, but impracticality limits their
use. Capecitabine (Xelodaw) is a selective, oral fluoropyrimi-
dine carbamate that generates 5-FU selectively in tumor tis-
sues. This selectivity is achieved by the enzyme thymidine
phosphorylase (TP), which is responsible for the final conver-
sion of capecitabine to 5-FU and is found at much higher levels
in gastric cancers than in normal tissues [2–5]. Capecitabine
offers the possibility of continuous tumor exposure to 5-FU by
preferential activation at the tumor site, while potentially mini-
mizing the exposure of healthy body tissues to systemic 5-FU.
In a Japanese clinical trial of 60 patients with previously
untreated advanced and metastatic gastric cancer, intermittent
capecitabine (828 mg/m2 twice daily for 3 weeks followed by
1 week of rest) led to a response rate of 25.5% and a median sur-
vival of 8.8 months [6]. A similar response rate (24%) has been
observed following administration of capecitabine in combi-
nation with epirubicin and cisplatin in 29 patients with inoper-
able esophago-gastric adenocarcinoma [7]. In both studies,
capecitabine-based therapy was well tolerated. To investigate
further the potential of capecitabine in this setting, we evalu-
ated the efficacy and safety of the global standard 3-weekly
intermittent capecitabine regimen in an open-label, multicenter,
non-comparative, phase II study of previously untreated
patients with advanced and/or metastatic gastric cancer.
Patients and methods
Eligible patients were between 18 and 75 years of age, and had histologi-
cally or pathologically confirmed advanced or metastatic, bidimensionally
measurable gastric cancer not amenable to curative surgery [World
Health Organization (WHO) criteria]. Patients were required to have
a Karnofsky performance status (KPS) >_70%, adequate renal, hepatic
*Correspondence to: Dr Jae Yong Cho, Yong-Dong Severance Hospital,
Yonsei University Medical College, Do-gok Dong, Kang-nam Gu,
Seoul, Korea. Tel: +82-2-3497-3310; Fax: +82-2-3463-3882;
E-mail: chojy@yumc.yonsei.ac.kr
Annals of Oncology 15: 1344–1347, 2004
doi:10.1093/annonc/mdh343



















and hematological functions, and a life expectancy of >3 months. All
patients gave written informed consent to participate. The protocol was
approved by the Korean Food and Drug Administration (FDA) and recog-
nized institutional review boards of each participating institution, and the
study was performed in accordance with the Declaration of Helsinki and
Good Clinical Practice.
A detailed medical history, physical and neurologic examinations, chest
X-ray, spiral computed tomographic (CT) scan of the abdomen, electro-
cardiogram, and pregnancy test for women were performed within the
2 weeks before study commencement. Run-in procedures, including vital
signs and clinical laboratory tests were performed within 7 days before
the start of chemotherapy.
Patients received oral capecitabine 1250 mg/m2 approximately every
12 h for 2 weeks, followed by 1 week of rest, every 3 weeks. Capecitabine
was supplied as film-coated tablets in two dose strengths (150 and 500 mg
tablets), which patients were instructed not to split. Patients with complete
remission (CR), partial remission (PR) or stable disease (SD), and who
were tolerating treatment well, were treated for up to six cycles. Those
with clearly documented progressive disease (PD) were taken off treat-
ment at the time of progression. Responding patients (CR or PR) or those
with SD after 18 weeks were followed until PD, and were able to continue
on capecitabine at the discretion of the investigator. Treatment doses were
not interrupted or reduced because of toxicities considered by the investi-
gator to be unlikely to become serious or life-threatening. The dosage was
adjusted or interrupted for treatment-related adverse events of grade >_ 2
based on a defined algorithm [8].
Tumor assessments, according to WHO criteria [9] were performed at
6-week intervals by the investigators and an Independent Review Commit-
tee (IRC). Tumor lesions were assessed by CT scan, X-rays or magnetic
resonance imaging (MRI), and objective tumor response was based on the
dimensions of measurable marker lesions, measured by the same radio-
logist throughout the study. TTP was calculated as the time from the first
treatment to the time the patient was first recorded as having PD, or the
date of death if the patient died before PD was demonstrated. Survival
was monitored every 3 months after the patient completed treatment.
Safety was monitored throughout the study and for 28 days after the last
study treatment. Adverse events were graded according to the National
Cancer Institute of Common Toxicity Criteria. Hand-foot syndrome (HFS)
was graded as in previous capecitabine studies [10]. Patients were edu-
cated to recognize grade >_ 2 toxicity and to interrupt capecitabine until
further instructed by their physician.
The response rate was expected to be  25% based on data from a pre-
vious Japanese phase II trial [6]. A sample size of 38 was calculated by
Fleming’s single-stage design [11] to ensure at least 80% power for prov-
ing lack of efficacy if the true response rate was <25%. Estimating a
drop-out rate of 15%, a total of 44 patients were recruited to ensure that at
least 38 patients were evaluable. TTP and survival were analyzed by the
Kaplan–Meier product limit method. Patients who received at least one
dose of study medication were included in the intention-to-treat (ITT) ana-
lysis. Those who did not receive at least one dose of study medication or
for whom no follow-up safety information was available were excluded
from the safety analysis.
Results
Patient characteristics
Of the 45 patients who were enrolled at four centers,
44 patients (35 men, nine women) received at least one dose
of capecitabine and were evaluable for efficacy and safety
(ITT population). One patient withdrew consent during the
screening period and did not receive capecitabine. As shown
in Table 1, the majority of patients (93%) had stage IV disease
and 59% had two or more metastatic sites, the most com-
monly affected sites being the lymph nodes (86%) and the
liver (45%). Twenty-three percent of patients had undergone
one or more type of surgery.
Efficacy
Fifteen of the 44 patients [34%; 95% confidence interval
(CI) 20%–50%] had a PR and 13 patients (30%) had SD
(investigator-determined responses; Table 2). The IRC deter-
mined that 14 patients (32%; 95% CI 19%–48%) had PR and
14 (32%) had SD (Table 2). The median TTP was 3.1 months
(95% CI 2.7–6.3 months) and the median overall survival was
9.5 months (95% CI 6.9–13.2 months) (Figure 1).
The median duration of treatment for all patients entered in
the study was 61 days (range 7–196 days). Sixteen (36%)
patients were treated for at least 18 weeks; of these, eight
(18%) were treated for >18 weeks in the continuation phase.
The median dose-intensity was 3541.5 mg/day and the median
cumulative dose of capecitabine was 182.5 g.
Table 1. Patient characteristics
n (%)a













































The most common treatment-related clinical adverse events
were HFS (68%), nausea (27%), diarrhea (27%) and anorexia
(21%). Most events were mild to moderate in severity and did
not exceed grade 2 (Figure 2). The predominant grade 3 toxi-
cities were HFS, diarrhea and anorexia. One patient experi-
enced a grade 4 genital rash, although no other grade 4
toxicity or toxicity-related deaths were reported. The most
common events leading to treatment modification were HFS,
nausea, vomiting, diarrhea, leukopenia and pyrexia.
Most clinical hematological and laboratory values were
stable or worsened by only one grade. Importantly, grade 3/4
myelosuppression (neutropenia, lymphocytopenia or anemia)
was not observed in any of the patients. The most common
grade 3 laboratory abnormality was a change in serum sodium
level (5%). No patient discontinued treatment because of
abnormal laboratory values.
There were 23 deaths reported during the study, the majority
of which occurred >28 days after the end of the planned treat-
ment schedule. All of the deaths were related to PD.
Discussion
The current findings show that capecitabine is active and well
tolerated as first-line treatment in patients with advanced
and/or metastatic gastric cancer. Despite overlapping confi-
dence intervals, our objective response rate of 34% compares
well with rates reported previously for other single agents
in patients with gastric cancer [12], including a less dose-
intensive Japanese regimen of capecitabine (828 mg/m2 twice
daily on days 1–21 of a 4-week cycle) [6]. While the usual
limitations of cross-study comparisons should be taken into
account when interpreting efficacy results, it is interesting to
note that the response rate is also comparable to the 28%
observed in 30 patients receiving docetaxel and 5-FU/LV
(leucovorin) for locally advanced and/or metastatic gastric
cancer in a recent Spanish phase II trial [13], and the 47%
response rate achieved with infusional 5-FU, cisplatin and
mitomycin C in 45 patients with advanced/metastatic gastric
cancer in a recent Italian phase II study [14]. While interpret-
ation of survival data in such a small group of patients is diffi-
cult because of selection bias, the median survival time
for patients receiving capecitabine in the current study
(9.5 months) is comparable to the times previously reported
for docetaxel and 5-FU/LV (7.7 months) and infusional 5-FU/
cisplatin/mitomycin C (11.0 months) in the first-line setting
[13, 14]. However, larger, randomized trials are required to
confirm these findings.
The median treatment duration was 61 days (range 7–196
days) and the mean relative dose intensity was 91%, which is
higher than that reported in previous studies in colon cancer
[15] and gastric cancer [6, 7]. The higher dose intensity in the
current study might be one of the possible explanations for
our higher response rate compared with the previous Japanese
trial reported by Kondo, in which patients received a lower
dose 4-weekly regimen [6]. It is also important to acknow-
ledge that 10 patients (23%) had undergone one or more surgi-
cal intervention for gastric cancer, which could impact on the
absorption of orally administered drugs. While there are no
pharmacokinetic data on the use of capecitabine in patients
following gastric surgery [16], neither our findings nor those
from previous studies of capecitabine suggest that previous
surgery impacts on the efficacy of capecitabine in this setting.
The safety profile of capecitabine in this trial is similar
to that observed with a 4-weekly capecitabine regimen in
Figure 1. Survival curve for all patients. Open circles indicate censored
observations.
Table 2. Efficacy data (intention-to-treat population, n = 44)
n (%)a 95% CI (%)
Investigator-assessed response
Overall best response (CR+PR)b 15 (34) 20–50
Complete response 0 (0) –
Stable disease 13 (30) 17–45
Progressive disease 12 (27) 15–43
Median TTP (months) 3.1 2.7–6.3
IRC-assessed response
Overall best response (CR+PR)b 14 (32) 19–48
Stable disease 14 (32) 19–48
aUnless otherwise stated.
bWorld Health Organization criteria.
CI, confidence interval; CR, complete remission; PR, partial remission;
TTP, time to disease progression; IRC, Independent Review Committee.
Figure 2. Most common treatment-related adverse events (>10% of




















patients with advanced/metastatic gastric cancer [6], capecita-
bine plus epirubicin, and cisplatin in patients with inoperable
esophago-gastric adenocarcinoma [7], and compares favorably
with that of 5-FU-based regimens in similar patient popu-
lations [13, 14]. Importantly, very few patients (5%) experi-
enced grade 3 diarrhea, and capecitabine was minimally
myelosuppressive and did not cause significant hair loss. The
predominant treatment-related grade 3 adverse event was HFS
(9%), which is a well known adverse event related to chronic
fluoropyrimidine exposure, and is one of the most commonly
reported adverse events following treatment with capecitabine
[17]. HFS is manageable with therapy interruption and, if
necessary, dose reduction, and is never life threatening.
These efficacy and safety findings, together with the striking
9:1 patient preference for oral rather than i.v. chemotherapy as
treatment for late-stage disease [18–20], indicate that capecita-
bine is unique among currently available treatments for gastric
cancer in that it is compatible with oral, patient-oriented,
home-based therapy. Larger, randomized trials of capecitabine,
either as a single agent or in combination with other highly
active drugs, possibly incorporating pharmacoeconomic and
quality of life end points, are clearly warranted in the first-line
setting. Ongoing phase III trials include a Korean study of
capecitabine/cisplatin versus 5-FU/cisplatin in patients with
previously untreated advanced/metastatic gastric cancer, and a
UK, four-arm trial evaluating capecitabine plus 5-FU and
oxaliplatin plus cisplatin in patients with advanced esophago-
gastric cancer [21].
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